-
ArticlePublication 2012Estimated Benefits of Atypical Antipsychotics in Schizophrenia: A Decision Model
This article, published in Annals of General Psychiatry, describes the development of a decision tree model …
This article, published in Annals of General Psychiatry, describes the development of a decision tree model with Markov processes to quantify the resources used and the corresponding burden of disease due to a projected reduction in relapse frequency resulting from further improvements in medication compliance in patients with schizophrenia. The analyses are conducted from the third party payer perspective and outcomes are modeled over a one-year and five-year time horizon. Three delivery technologies are compared: a…
North America | Mathematical Models | State-Transition | Cost-Effectiveness Analysis | Mental Health | Health/Medicine -
ArticlePublication 2016Cost-Effectiveness of Off-Label Antipsychotics in Children and Adolescents
This article, published in Attention Deficit and Hyperactivity Disorders, presents a decision tree to evaluate …
This article, published in Attention Deficit and Hyperactivity Disorders, presents a decision tree to evaluate the cost-effectiveness of atypical antipsychotics (AAPs) to other non-stimulant ADHD medications in treating children and adolescents with ADHD who failed initial stimulant treatment. The strategies compared in the analysis are: (1) AAPs, (2) a selective norepinephrine reuptake inhibitor (atomoxetine), and (3) selective α2-adrenergic agonists (clonidine and guanfacine). Data on the input parameters of the model are derived from the literature.…
North America | Mathematical Models | Cost-Effectiveness Analysis | Mental Health | Health/Medicine -
ArticlePublication 2006Costs & Benefits of Enhanced Depression Care to Employers
This article, published in the Archives of General Psychiatry, aims to estimate the cost-effectiveness of …
This article, published in the Archives of General Psychiatry, aims to estimate the cost-effectiveness of a program of enhanced depression care, specifically for workers compared to usual care from the societal perspective in a cohort of 40-year-old employees in the US. The authors also conduct a cost-benefit analysis from the perspective of the employer-purchaser over a 5-year time frame. From the societal perspective, the results indicate that screening and depression care management for workers…
North America | State-Transition | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Mental Health | Health/Medicine -
ArticlePublication 2017Costs and Benefits of Insuring Psychological Services for Depression in Canada
This article, published in Psychiatric Services, describes the development of a discrete event simulation model …
This article, published in Psychiatric Services, describes the development of a discrete event simulation model to investigate the costs and effects of increasing access to publicly-funded psychotherapy for depression compared to the status quo in a public health care system in Canada. The analyses from both the societal and health system perspective are conducted over a 40-year time horizon. Data on the probability of events, costs (direct and indirect), and utility estimates are obtained from…
North America | Microsimulation | Cost-Effectiveness Analysis | Mental Health | Health/Medicine -
ArticlePublication 2012Modeling the Risks and Benefits of Depression Treatment for Children and Young Adults
This article, published in Value in Health, presents a discrete event simulation model to quantify …
This article, published in Value in Health, presents a discrete event simulation model to quantify the trade-offs with respect to clinical benefits and the risk of fatal and non-fatal suicidal behavior of alternative treatment strategies for a U.S. pediatric population with major depressive disorder. The authors evaluate treatment strategies including: selective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy (CBT), and a combination of both. The results show that the use of SSRIs is associated with…
North America | Health Outcomes | Microsimulation | Technology Assessment | Mental Health | Health/Medicine -
ArticlePublication 2014Cost-Effectiveness of Asenapine in the Treatment of Bipolar Disorder in Canada
This article, published in BMC Psychiatry, presents a decision tree combined with a Markov model …
This article, published in BMC Psychiatry, presents a decision tree combined with a Markov model that estimates the cost-effectiveness of asenapine compared with olanzapine in the treatment of bipolar disorder in Canada. The decision tree part of the model takes into account the occurrence of extrapyramidal symptoms, the probability of switching to a different antipsychotic, and the probability of gaining weight. The Markov model part takes into account the long-term metabolic complications including diabetes, hypertension,…
North America | Mathematical Models | State-Transition | Cost-Effectiveness Analysis | Mental Health | Health/Medicine -
ArticlePublication 2014Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness …
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness of alternate sequences of treatment strategies using second-generation antipsychotics (SGAs) for patients with schizophrenia. First-line treatments include one of the four SGAs: olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone (ZSD). Patients are able switch to another of these antipsychotics as second-line therapy, and only clozapine (CLZ) is allowed as third-line treatment. Model input parameters were obtained from the Clinical…
North America | State-Transition | Cost-Effectiveness Analysis | Mental Health | Health/Medicine
7 Shown
General Resources
Teaching Resources
Collections
Format
Learner Level
Teaching Topic